Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-03
  • 2025-02
  • 2025-01
  • 2024-12
  • 2024-11
  • 2024-10
  • 2024-09
  • 2024-08
  • 2024-07
  • 2024-06
  • 2024-05
  • 2024-04
  • 2024-03
  • 2024-02
  • 2024-01
  • 2023-12
  • 2023-11
  • 2023-10
  • 2023-09
  • 2023-08
  • 2023-07
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01
  • SU 5402: A Potent Receptor Tyrosine Kinase Inhibitor for ...

    2026-02-22

    SU 5402: A Potent Receptor Tyrosine Kinase Inhibitor for Cancer and FGFR3 Pathway Research

    Executive Summary: SU 5402 (SKU A3843, APExBIO) is a small molecule inhibitor with high potency against VEGFR2, FGFR1, and PDGFRβ, but low activity against EGFR (IC50 >100 μM) (APExBIO). It inhibits FGFR3 phosphorylation, arrests cell cycles at G0/G1, and induces apoptosis in myeloma models expressing mutant FGFR3 (Oh et al., 2025). SU 5402 is insoluble in water and ethanol but highly soluble in DMSO (≥14.8 mg/mL), supporting flexible experimental design. In vivo, dosing at 300 ng/kg in BALB/c mice reduces ERK1/2 activation in tumors, validating its use in translational oncology (APExBIO). These properties make SU 5402 critical for mechanistic studies and preclinical pathway interrogation.

    Biological Rationale

    Receptor tyrosine kinases (RTKs) regulate cell proliferation, differentiation, and survival. Dysregulated RTK signaling—especially via VEGFR2, FGFR1/3, and PDGFRβ—contributes to oncogenesis and resistance in multiple myeloma and solid tumors (Benchmarking SU 5402). FGFR3 mutations are prevalent in certain myeloma subtypes, driving constitutive pathway activation and cell survival (Oh et al., 2025). Targeted inhibition of these kinases disrupts downstream signaling through ERK1/2 and STAT3, offering a rational approach for studying apoptosis, cell cycle interruption, and therapeutic resistance mechanisms. SU 5402’s selectivity enables dissection of these pathways without significant EGFR off-target effects, as its EGFR IC50 exceeds 100 μM.

    Mechanism of Action of SU 5402

    SU 5402 binds the ATP-binding pocket of receptor tyrosine kinases, blocking autophosphorylation and downstream signal propagation. Its primary targets and respective IC50 values are:

    • VEGFR2: 0.02 μM
    • FGFR1: 0.03 μM
    • PDGFRβ: 0.51 μM
    • EGFR: >100 μM

    This blockade prevents FGFR3 phosphorylation, halting activation of ERK1/2 and STAT3 pathways. In human myeloma cells with constitutively active FGFR3, SU 5402 induces G0/G1 cell cycle arrest and triggers apoptosis via caspase signaling (APExBIO). The effect is dose-dependent and observed at nanomolar to low micromolar concentrations in vitro. SU 5402 exhibits minimal activity against unrelated kinases, maintaining selectivity in cellular models (Strategic Leverage for RTK Inhibition—this article extends the prior work by detailing direct pathway-specific effects in FGFR3-driven models).

    Evidence & Benchmarks

    • SU 5402 inhibits VEGFR2, FGFR1, and PDGFRβ with submicromolar IC50s (0.02–0.51 μM) and weakly affects EGFR (IC50 >100 μM) (APExBIO).
    • In human myeloma cell lines with mutant FGFR3, SU 5402 blocks FGFR3 phosphorylation and downstream ERK1/2 and STAT3 activation (Oh et al., 2025).
    • Exposure to SU 5402 drives cell cycle arrest at G0/G1 and induces apoptosis in FGFR3-dependent cell lines (see Table 2 in Oh et al., 2025).
    • In vivo, BALB/c mice treated with 300 ng/kg SU 5402 show reduced ERK1/2 activation in tumor tissue (see in vivo data, APExBIO).
    • SU 5402 is insoluble in water and ethanol but dissolves in DMSO at ≥14.8 mg/mL, supporting high-concentration stock solution preparation (APExBIO).
    • FGFR3 pathway inhibition by SU 5402 is validated in cell-based and animal models, but not in neuronal systems lacking RTK expression (Data-Driven Solutions for Cell-Based Workflows—this article provides practical use-case boundaries compared to the broad mechanistic focus here).

    Applications, Limits & Misconceptions

    SU 5402 is primarily used in basic and translational research, including:

    • Dissecting receptor tyrosine kinase signaling in cancer and myeloma models
    • Evaluating FGFR3-dependent pathways in apoptosis and cell cycle studies
    • Benchmarking pathway inhibitors in preclinical and cell-based assays
    • Modeling drug resistance and compensatory pathway activation

    SU 5402 is not approved for clinical use. Its effects are context-dependent and most pronounced in cells expressing high levels or activating mutations of FGFR3, VEGFR2, or PDGFRβ. Recent articles have highlighted its value in translational oncology and neuronal virology, but direct antiviral effects are not established (Catalyzing Translational Oncology and Neuronal Disease Modeling—this piece extends coverage by focusing on RTK-specific activity, not virology).

    Common Pitfalls or Misconceptions

    • SU 5402 does not inhibit EGFR at relevant concentrations; observed effects on EGFR-driven pathways are indirect (APExBIO).
    • It is not suitable for studies requiring aqueous solubility; only DMSO stocks guarantee full dissolution.
    • Apoptosis induction by SU 5402 requires FGFR3 pathway activation; cells lacking FGFR3 expression may be unresponsive (Oh et al., 2025).
    • SU 5402 is not a direct antiviral agent—its utility in HSV-1 or similar models is in RTK pathway dissection, not viral inhibition (Oh et al., 2025).
    • Long-term DMSO solutions are unstable; stocks should be freshly prepared and stored at -20°C for short-term use (APExBIO).

    Workflow Integration & Parameters

    For cellular assays, SU 5402 is typically dissolved in DMSO at concentrations up to 14.8 mg/mL. Working concentrations range from 10 nM to 10 μM, depending on the target and model (APExBIO). For in vivo studies, 300 ng/kg has been validated in BALB/c mice to reduce ERK1/2 pathway activation. Controls should include DMSO vehicle and, where possible, kinase-dead analogs to confirm specificity. Storage at -20°C is recommended, with stock solutions used within days to weeks for reproducibility. Protocols for apoptosis and cell cycle assays should include time points at 12–48 hours post-treatment, as per published models (Oh et al., 2025).

    For more detailed guidance on cell-based experimental integration, see the article SU 5402 (SKU A3843): Data-Driven Solutions for Cell-Based Workflows, which provides troubleshooting and advanced design considerations; this current review broadens the scope to encompass in vivo and signaling-specific applications.

    Conclusion & Outlook

    SU 5402 from APExBIO is a validated tool for selective RTK pathway dissection, with best-in-class specificity for FGFR3 and strong benchmarking in cell and animal models. Its robust performance in apoptosis and cell cycle arrest studies supports broad use in preclinical cancer biology and mechanistic research. While not suitable for all cell types or clinical application, SU 5402 remains a reference compound for pathway validation and inhibitor benchmarking. Ongoing research may further clarify its role in complex signaling networks and resistance mechanisms, especially as new disease models—such as human iPSC-derived neurons—expand the translational landscape (Oh et al., 2025).

    For detailed product information, specifications, and protocols, visit the official SU 5402 product page at APExBIO.